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OBJECTIVE — We determined the relationships between glycemia at randomization, con-
current antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients
withdiabetesreceivingstandardtreatmentfordiabetesandrandomizedtoranolazineorplacebo
withintheMERLIN-TIMI-36(MERLIN)study.Ranolazineisanovelﬁrst-in-classdrugapproved
for treating angina pectoris.
RESEARCH DESIGN AND METHODS — Randomization and 4-month glycemic and
antidiabetes drug usage data from MERLIN were analyzed using Spotﬁre and SAS version 9.1
software.
RESULTS — In patients with diabetes and A1C of 8–10% at randomization (n  171),
there was an absolute A1C reduction in the ranolazine group of 1.2% (95% CI 1.4 to 1.0),
and the placebo-adjusted (n  182) decrease in A1C by ranolazine was 0.59% (95% CI 0.99
to0.20,P0.001).InpatientswithFPGof150–400mg/dlatrandomization,ranolazine(n
131)comparedwithplacebo(n147)reducedFPGby25.7mg/dl(95%CI43.3to8.1,P
0.001). When changes in either A1C or FPG were correlated to A1C or FPG at randomization,
the slopes were signiﬁcantly steeper for ranolazine than placebo (A1C, P  0.046; FPG, P 
0.001), indicating that lowering of A1C and FPG by ranolazine is related to hyperglycemia at
randomization. Ranolazine, compared with placebo, was not associated with serious hypogly-
cemic events, associated with signiﬁcant changes in concurrent antidiabetic therapy, or depen-
dent on a history of angina.
CONCLUSIONS — Ranolazine, when added to concurrent antidiabetes treatment, lowers
FPG and A1C in patients with cardiovascular disease and poorly controlled diabetes.
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D
iabetes is an established risk factor
for cardiovascular disease, and the
risk of cardiovascular disease in-
creases with worsening hyperglycemia
(1–3). Furthermore, coronary artery dis-
easeisthemostcommoncauseofdeathin
patients with diabetes (4). Patients with
coronaryarterydiseaseandarecentmyo-
cardialinfarctionoracutecoronarysyn-
drome (ACS) have an increased
incidence of impaired fasting plasma
glucose (FPG) and new-onset diabetes
(5–7). Management of diabetes in pa-
tients with cardiovascular disease is
complicated by the fact that the cardio-
vascular safety of some oral glucose–
lowering agents has been questioned,
and outcome data are lacking (8).
Ranolazine is a ﬁrst-in-class anti-
anginal drug with cardioprotective prop-
erties without effects on heart rate or
blood pressure (9). The drug inhibits the
cardiac late sodium current (10,11). The
late sodium current is enhanced during
ischemia and in the failing heart and con-
tributes to the Na-dependent cellular
calcium overload associated with these
pathological conditions (10,11). Ranola-
zine has been shown effective in treating
chronic angina both as a monotherapy
(MARISA trial) and in combination with
commonly prescribed cardiovascular
drugs (CARISA and ERICA trials) (12–
14), with no increase in mortality in pa-
tients with established coronary artery
disease, including those with diabetes
(15,16).
Post hoc analysis of data from the
CARISA study demonstrated that ranola-
zineloweredA1C,along-termbiomarker
of glucose control, in patients with
chronic angina and diabetes, in a dose-
dependentmanner(17).Whilethemech-
anism of glycemic improvement remains
incompletely understood, preliminary
studiesusingisolatedratandhumanpan-
creatic islets suggest ranolazine may pro-
moteglucose-stimulatedinsulinsecretion
(18).
In the MERLIN-TIMI-36 (MERLIN)
study, the effects of ranolazine to lower
A1C and glucose were conﬁrmed using
prespeciﬁed glycemic end points (16). In
this study, patients with diabetes were re-
ceiving standard of care treatment for di-
abetes with mean A1C levels of 7.5% at
randomization. Despite the relatively low
mean A1C at randomization, ranolazine
was found to signiﬁcantly reduce A1C in
patients with diabetes and to reduce the
incidence of newly elevated A1C in ini-
tially normoglycemic patients (16). The
mean placebo-corrected reductions in
A1C with ranolazine treatment at 4
months were 0.42% (P  0.001) and
0.18% (P  0.001) for patients with and
without diabetes, respectively. There
were no differences in the reported inci-
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and ranolazine.
The glucose-lowering response to
multiple antidiabetic therapies is greater
in patients with higher baseline A1C and
glucose values (19). Therefore, the cur-
rent analysis of the MERLIN data was un-
dertaken to evaluate the effects of
ranolazine on FPG and A1C in diabetic
patients with moderate or severe hyper-
glycemia, deﬁned as an A1C of 6 to 8%
or 8–10%, or FPG 150 or 150–
400 mg/dl, respectively, at randomiza-
tion. Additionally, MERLIN data were
assessed as to whether effects of ranola-
zine on glycemia were inﬂuenced by con-
current antidiabetic therapy.
RESEARCH DESIGN AND
METHODS
Study overview
In the MERLIN trial, 6,560 patients with
non-ST elevation ACS with at least one
marker of moderate-to-high risk of recur-
rent ischemic events (including diabetes)
were randomized at 440 sites in 17 coun-
tries. The study design, investigators, pri-
mary results of the trial, and prespeciﬁed
end points of glycemic control have been
reported(15,16,20,21).Aspreviouslyde-
scribed (20), eligible patients were ran-
domly assigned by a central interactive
voice response system in a 1:1 ratio to
receive either ranolazine or placebo,
which was initiated as an intravenous in-
fusion and followed by oral administra-
tionatadoseof1,000mgtwicedailyuntil
the end of the study. Randomization was
stratiﬁed by “intention to manage the pa-
tient with early invasive strategy (angiog-
raphywithin48handrevascularizationif
necessary).” There was no stratiﬁcation
based on the presence of new or estab-
lished diabetes. Patients returned for
study visits at 14 days, 4 months, and ev-
ery 4 months thereafter until the end of
the study at 16 months.
After patient interviews and review of
medical records, investigators recorded a
history of diabetes and its treatment on
study case record forms. Patients with di-
abetes, regardless of treatment group, re-
ceived standard of care treatment for
diabetes, and there was no prespeciﬁed
glycemic goal. The protocol stipulated
that A1C and plasma glucose were to be
measured locally at randomization (me-
dian 24 h after symptom onset), 4
months, 8 months, 16 months, and the
ﬁnal study visit, with data recorded in the
case report form as to whether the patient
was fasting or not.
Statistical analysis
Patients with A1C values at randomiza-
tion and month 4 were included in this
retrospective exploratory analysis per-
formed using Spotﬁre Software (Tibco
Software, Somerville, MA). In addition,
FPG was assessed in patients with fasting
measures. Spotﬁre ﬁltering and visualiza-
tion tools were used speciﬁcally to search
thedatasetforrelationshipsbetweenA1C
and glucose at different levels of glycemic
control. For each analysis, the studied
population is described in the corre-
sponding ﬁgure legend and the analysis
was reproduced in SAS Version 9.1 (SAS,
Cary, NC) as described below.
Analyses of change from randomiza-
tion in A1C, and separately FPG, were es-
timated by two models. The ﬁrst model
usedANCOVAincludingfactorsfortreat-
ment, the randomization covariate of
interest, and the randomization stratiﬁca-
tion variable. The randomization covari-
ate categories for A1C and FPG were
deﬁned to include all nonmissing ran-
domization values. The second model, a
detailed analysis of treatment differences
withincovariatelevels,waspreparedwith
a cell means version of the linear model.
The cell means model included an inter-
cept and one factor for each combination
of treatment and randomization covariate
category and a single factor for the ran-
domization stratiﬁcation variable. The es-
timates of the treatment effects from the
analyses of covariance are least square
means. A Tukey-Kramer procedure was
usedtoestimatetheconﬁdencelimitsand
P value. The analyses were performed us-
ing proc mixed, in SAS Version 9.1 (SAS,
Cary, NC).
All medications and dosages were re-
corded at each study visit by the investi-
gator. Changes in antidiabetic therapy
were described as changes in the number
or dosage of hypoglycemic agents. Pa-
tients were categorized as having an
increase, decrease, or no change in con-
current antidiabetes therapy. In complex
cases, the records were evaluated by ex-
pert review while blinded to treatment. A
smallnumberofpatientrecordscouldnot
be categorized because of nonsensical
dataandwereomittedfromthefrequency
analysis. Differences in intensiﬁcation
andde-intensiﬁcation(decreaseinantidi-
abetictherapy)frequenciesbetweentreat-
ment groups were determined by 
2
analysis.
RESULTS
Study population
The current analysis includes patients
with A1C data and/or fasting glucose data
andahistoryofdiabetesmeasuredatboth
randomization and 4 months. Of the pa-
tients (placebo 2,679, ranolazine 2,565)
reaching month 4 (supplementary Ta-
ble A1, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-2334/DC1), one-third
had a history of diabetes (placebo 892,
ranolazine 842). Eighty-ﬁve percent of
the patients with diabetes had A1C mea-
surements at both randomization and
month 4 (placebo 770, ranolazine 707),
and 35% had FPG measurements at both
times (placebo 328, ranolazine 310). All
patients had access to standard of care
antidiabetes treatment, and baseline
characteristics were similar for the pla-
cebo- and ranolazine-treated groups
(Table 1). The mean A1C and FPG val-
ues at randomization for patients in-
cluded and excluded from this analysis
because of missing data at randomiza-
tion or month 4 were not different.
Effect of ranolazine on A1C and FPG
The diabetes study population was di-
vided into good/moderate and poor gly-
cemic control groups deﬁned as A1C 6 to
8%or8–10%.Therewasasigniﬁcant
reduction in A1C with ranolazine in ad-
dition to standard of care antidiabetes
treatmentforboththeA1C6to8%and
A1C 8–10% groups (Fig. 1A). The ab-
solutereductioninA1Cintheranolazine-
treated patients with better glycemic
control(A1C6to8%)was0.28%(95%
CI 0.38 to 0.19), and for individuals
with poorer glycemic control (A1C 8–
10%), A1C was reduced 1.2% (95% CI
1.4 to 1.0). The placebo-corrected
decrease in A1C with ranolazine was
0.28% (95% CI 0.55 to 0.00, P 
0.045) for the A1C 6 to 8% group
and 0.59% (95% CI 0.99 to 0.20, P 
0.001) for patients with A1C 8–10%.
In this study, the FPG level at ran-
domization corresponding to an A1C of
8%was150mg/dl(datanotshown).As
a result, patients (placebo n  327, rano-
lazine n  306) were similarly divided
intotwogroups:good/moderateglycemic
control (150 mg/dl) and poor glycemic
control (150–400 mg/dl, Fig. 1B). The
FPG 150 mg/dl group was limited to
400 mg/dl to exclude ﬁve patients with
very high initial FPG values and potential
confounding concomitant illnesses.
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reduction in FPG of 25.7 mg/dl (95% CI
43.3 to 8.1, P  0.001) by ranolazine
for patients with marked hyperglycemia
(FPG 150–400 mg/dl), whereas there
wasnochangeinFPG(6.8mg/dl,95%CI
8.8 to 22.3, P  0.68) in those patients
with normal to moderate fasting hyper-
glycemia (FPG 150 mg/dl).
The ﬁnding that both A1C and FPG
loweringbyranolazineweregreaterinhy-
perglycemicpatientssuggestedarelation-
ship between glycemia at randomization
and A1C or FPG lowering by ranolazine.
As shown in Fig. 1C, there was a linear
relationship between A1C at randomiza-
tion and decrease in A1C with both pla-
cebo and ranolazine. However, the
inverse relationship was stronger for
ranolazine (R  0.41 vs. R  0.26 for
placebo), and the slope was signiﬁcantly
steeper for ranolazine (slope  0.44
[95% CI 0.53 to 0.36]) compared
with placebo (slope  0.31 [95%
CI 0.41 to 0.21], P  0.046). Simi-
larly, when FPG at randomization was
correlated with the change in FPG at 4
months, there was a linear relationship
between FPG at randomization and de-
crease in FPG with treatment (Fig. 1D).
The inverse relationship was stronger for
ranolazine (R  0.72 vs. R  0.48 for
placebo), and the slope was signiﬁcantly
steeper for ranolazine (slope  0.79
[95% CI 0.88 to 0.70]) compared
with placebo (slope  0.51 [95% CI
0.6 to 0.42], P  0.001). The linear
regression lines intersected at an FPG
value of 141 mg/dl (Fig. 1D), indicating a
greater effect for ranolazine than placebo
in lowering FPG in patients with FPG
141 mg/dl. This ﬁnding is consistent
withthepreviousanalysis(Fig.1B)show-
ing that ranolazine did not lower mean
FPG in patients with more moderate dys-
glycemia (FPG 150 mg/dl), whereas it
did lower FPG in individuals with more
marked hyperglycemia (FPG 150
mg/dl). In patients without a history of
diabetes, but with new or undiagnosed
diabetes, as deﬁned by an A1C of 6.5–
Figure 1—Relationship between glycemia at randomization and lowering of A1C and FPG by ranolazine in patients with a history of diabetes. A:
In a cell means model, with parameters for combinations of treatment, A1C category, and diabetes, the placebo-adjusted effect of ranolazine on A1C
was0.28%(95%CI0.55to0.003,P0.045)forpatientswithA1C6to8%and0.59%(0.99to0.20,P0.001)forpatientswithA1C
8–10%. B: In a cell means model, with parameters for combinations of treatment, FPG category, and diabetes, the placebo-adjusted effect on FPG
forthesepatientswas6.8mg/dl(95%CI8.8to22.3,P0.677)forpatientswithFPG150mg/dland25.7mg/dl(43.3to8.1,P0.001)
for patients with FPG 150–400 mg/dl. Changes in A1C and FPG at month 4 are summarized by mean, associated 95% CI, and number of patients
(n). C: Relationship between A1C at randomization and the change in A1C at month 4. The slope for placebo was 0.31 (95% CI 0.41 to 0.21),
R  0.26 and n  558. For ranolazine, the slope was 0.44 (0.53 to 0.36), R  0.41 and n  508. The slopes were signiﬁcantly different (P 
0.045). D: Relationship between FPG at randomization and the change in FPG at month 4. The slope for placebo was 0.55 (95% CI 0.64 to
0.46),R0.54andn328.Forranolazine,theslopewas0.81(0.89to0.73),R0.76andn310.Theslopesweresigniﬁcantlydifferent
(P  0.001). Least squares regression was performed by Graphpad Prism 5.0, and the best-ﬁt line and 95% CI for the ﬁt are shown for each group.
Similar results were obtained using an ANCOVA model with a term for treatment, A1C or FPG at randomization, and the interaction of treatment.
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effect of ranolazine to reduce FPG and
A1C was similar to that observed pa-
tients with a history of diabetes at com-
parable mean baseline A1C and FPG
levels (supplementary Table A2).
Angina history and glycemic
lowering by ranolazine
All patients (n  1,477) in the present
analysis had ACS, and 65% also had a
history of angina. Thus, the effect of an-
gina status on glucose lowering by rano-
lazine was determined. The placebo-
corrected change in A1C by ranolazine
was independent of angina history (P 
0.213; angina: 0.5%, 95% CI 0.9 to
0.1, P  0.014; no angina: 0.8%,
95% CI 1.2 to 0.3, P  0.001; sup-
plementary Fig. 1A). The absolute A1C
reduction in ranolazine-treated patients
with and without angina was 1.1% (95%
CI 1.4 to 0.9) and 1.2% (1.5 to
0.9), respectively. In patients having an
FPG of 150–400 mg/dl, the placebo-
corrected effect of ranolazine (angina:
26.2 mg/dl, 95% CI 48.2 to 4.3,
P0.02;noangina:25.1mg/dl,49.5
to 0.7, P  0.04) on FPG was indepen-
dent of a history of angina (P  0.408;
supplementary Fig. 1B). Therefore, rano-
lazine improves glycemia equally in pa-
tients with or without history of angina
pectoris.
Concurrent antidiabetic therapy
The usage rate and type of antidiabetic
therapy for placebo- and ranolazine-
treated patients with a history of diabetes
was similar between both ranolazine- and
placebo-treated groups at month 4 (Table
1). The majority of patients were taking
either a biguanide (metformin) (placebo
37.4%; ranolazine 36.4%) and/or a sulfo-
nylurea (placebo 39.4%; ranolazine
42.9%). There were no major differences
in insulin, thiazolidinedione, -glucosi-
dase inhibitor, or meglitinide usage. Ad-
ditionally, the frequency of patients
receiving monotherapy (placebo 50.0%;
ranolazine 47.4%) and dual therapy (pla-
cebo28.3%;ranolazine28.9%)fordiabe-
tes was similar between placebo and
ranolazine groups. When changes to an-
tidiabetic therapy (new or intensiﬁed hy-
poglycemic therapy) were evaluated
between 0 and 4 months, there were no
signiﬁcant differences between the pla-
cebo and ranolazine groups within any of
the study populations. As a result, the ef-
fect of ranolazine to lower FPG and A1C
does not appear to be attributable to in-
tensiﬁcation of concurrent antidiabetic
therapy in ranolazine-treated patients.
Similarly,areductioninantidiabeticther-
apy could underestimate the effect of
ranolazine to lower A1C and FPG; how-
ever, there were no signiﬁcant differences
inthefrequencyofreductionsinhypogly-
cemic agents between placebo and rano-
lazine in any of the study populations.
Furthermore, there were no signiﬁ-
cantdifferencesinthereportednumberof
severe hypoglycemic adverse events be-
tween placebo- and ranolazine-treated
patients between randomization and
month 4 (placebo 16; ranolazine 19, P 
0.69).
Probability of ranolazine-treated
patients achieving an A1C goal of
<7% by antidiabetic treatment
Patients with a history of diabetes were
divided into three groups based on the
type of antidiabetic treatment (supple-
mentary Table A3): no antidiabetes drugs
(placebo 16.6%, ranolazine 19.0%), oral
hypoglycemic agents (OHAs) but no in-
sulin(placebo55.2%,ranolazine53.7%),
andinsulinwithorwithoutanycombina-
tion of other diabetes drugs (insulin 	
OHA,placebo28.2%,ranolazine27.3%).
To determine whether the effect of A1C
lowering by ranolazine was inﬂuenced by
concurrent antidiabetic therapy, the odds
ratio(OR)forapatientwithanA1C7%
at randomization to achieve an A1C of
7% after 4 months on ranolazine, com-
pared with placebo, was calculated (Fig.
2). The OR for all patients with a history
of diabetes and an A1C 7% (placebo
399, ranolazine 378) was 1.6 (95% CI
1.2–2.2, P  0.001). The ORs for the re-
spective subgroups were as follows: no
antidiabetic drugs (placebo 34, ranola-
zine 37), OR 1.7 (95% CI 0.7–4.3, P 
0.24); OHA (placebo 219, ranolazine
203), OR 1.9 (1.4–2.5, P  0.001); and
insulin 	 OHA (placebo 146, ranolazine
138), OR 1.6 (1.1–2.3, P  0.007).
Whereas there were few patients not re-
ceiving antidiabetes pharmacologic ther-
apy, the OR favored ranolazine and
indicated that patients taking ranolazine
had a 60–90% greater probability of
achieving an A1C 7% than did patients
not taking ranolazine. Furthermore, the
effectofranolazinetolowerA1Cdoesnot
appear to be modulated by the type of
concurrent antidiabetic therapy. Consis-
tent with this observation, the placebo-
corrected effect of ranolazine on A1C in
patients with an A1C of 6–10% catego-
rizedbyconcomitantdiabetesmedication
was similar among groups (no diabetes
drugs, metformin only, sulfonylureas
only, metformin plus sulfonylurea, and
insulin only; supplementary Fig. 2).
CONCLUSIONS — Findings from
the MERLIN trial demonstrate that rano-
Table 1—Patient characterization at randomization and antidiabetic drug usage data at 4
months for patients with a history of diabetes
Patient characteristics at randomization Placebo Ranolazine
n 770 707
Age (years) 
median (25th to 75th percentile) 64 (57–71)* 65 (57–72)*
Female sex (%) 39.6* 43.2*
Weight (kg/m
2) 
median (25th to 75th percentile) 85 (75–96)* 84 (74–95)*
BMI (kg/m
2) 
median (25th to 75th percentile) 30 (27–33)* 30 (27–33)*
Hypertension (%) 84.4* 84.5*
Hyperlipidemia (%) 73.8* 75.9*
Current smoker (%) 19.5* 17.4*
Antidiabetes drug usage 
%( n)
Sulfonylurea 39.4 (303) 42.9 (303)
Biguanide (metformin) 37.4 (288) 36.4 (257)
Insulin 28.2 (217) 27.3 (193)
Thiazolidinedione 5.5 (42) 4.2 (30)
-Glucosidase inhibitor 2.9 (22) 3.0 (21)
Meglitinide 2.3 (18) 1.4 (10)
No antidiabetic drug 16.6 (128) 19.0 (134)
Monotherapy 50.0 (385) 47.4 (335)
Dual therapy 28.3 (218) 28.9 (204)
Three or more drugs 5.0 (38) 4.8 (34)
*Patient characterization data are reproduced from Morrow et al. (16).
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tory of diabetes (13,16,17). The current
analysis of the MERLIN data extends
these observations by examining the rela-
tionships between A1C and FPG concen-
trations at randomization and the
magnitude of the glycemic-lowering ef-
fectofranolazinewhenaddedtostandard
of care. Consistent with the efﬁcacy of
otherantidiabeticdrugs,A1Cloweringby
ranolazine was greater in patients with
more marked hyperglycemia (A1C 8–
10% or FPG 150–400 mg/dl at ran-
domization). While the magnitude of
A1C lowering with ranolazine compared
with placebo may appear small, it is im-
portant to recognize that effects were as-
sessed as add-on to established therapies
with dose adjustments of concomitant
medications permitted. This is not typical
for studies examining glycemia as the pri-
mary end point. Ranolazine was not asso-
ciated with increased rates of severe
hypoglycemicadverseevents.Theseﬁnd-
ings are particularly noteworthy, since
ranolazine has established cardiovascular
safety in patients with ACS, a particularly
vulnerablepopulationthathasbeeninfre-
quently investigated during early devel-
opment of diabetes-speciﬁc therapies.
Furthermore, ranolazine appears
more effective than placebo for glycemic
improvement regardless of background
antidiabetes therapy. For patients with
A1C 7%, above the current treatment
goal recommended by the American Dia-
betesAssociationandtheEuropeanAsso-
ciation for the Study of Diabetes (22), the
effect of ranolazine to lower A1C to 7%
appears independent of the concurrent
antidiabetic therapy. The lack of signiﬁ-
cant effect in patients with diabetes not
receiving antidiabetes drugs may be ex-
plained by the very low number of pa-
tients in this group with an initial A1C
7% (placebo 34, ranolazine 37). Addi-
tionally, both treatment groups had very
large improvements in A1C at 4 months
(placebo 0.9%, ranolazine 1.3%),
perhaps representing more newly diag-
nosed disease or increased physician or
patient attentiveness.
Ranolazine signiﬁcantly reduced pla-
cebo-adjustedFPGby25.7mg/dlinpa-
tients with elevated FPG (150–400
mg/dl), but not in patients with milder
dysglycemia (FPG 150 mg/dl) at ran-
domization. This ﬁnding is in agreement
with data from adverse event reporting,
indicating that ranolazine is not associ-
ated with excess hypoglycemia compared
with placebo. In the subgroup of diabetes
patients with better glycemic control
(FPG 150 mg/dl) treated with a sulfo-
nylurea, changes in FPG were similar be-
tween placebo and ranolazine, suggesting
that the risk of hypoglycemia with a sul-
fonylurea is not increased by ranolazine.
It is noteworthy that ranolazine previ-
ously has been shown to reduce incident
diabetes by 32% (16).
Patients in the study with a history of
diabetes generally had good/moderate
glycemic control (placebo A1C 7.4%;
ranolazine A1C 7.5%) at study entry, and
all patients received regular medical and
antidiabeticcare.Asaresult,boththepla-
cebo and ranolazine treatment groups
had improvements in glycemic control.
Therewasnostabilizationperiodpossible
in the MERLIN trial, as the enrollment
eligibility was based on having an ACS
event followed by immediate stratiﬁed
randomization and initiation of treatment.
Furthermore,thestudydesignlimitsthedi-
rectcomparisonoftheantidiabeticeffectsof
ranolazine with other drugs evaluated in
conventional antidiabetic drug trials.
These results indicate that the previ-
ously reported lowering of A1C by rano-
lazine is positively correlated with A1C
levels at randomization and is associated
with a reduction in FPG in patients with
hyperglycemia (13,16). These ﬁndings
address the previous concern of a poten-
tial lack of correlation between A1C and
glucose changes with ranolazine (13,16).
We have focused exclusively on the
patients who had glycemic data available
atbothrandomizationand4monthspos-
trandomization for the following reasons.
The average duration of treatment in the
trial was 8 months (16); however, 4
months is sufﬁcient time to evaluate
changes in A1C, and the number of pa-
tients with a history of diabetes and gly-
cemic data was greater at 4 (n  1,477)
than at 8 (n  1,133) and 16 (n  234)
months. Moreover, because this was an
intent-to-treat trial, the 4-month time
minimizes the impact of the patients in
the ranolazine group who were no longer
taking ranolazine. The discontinuation
ratefortheplaceboandranolazinegroups
duringtheentirestudyperiodwas22and
28%, respectively (15). While nearly all
patients had glucose measurements at 0
and 4 months, fasting was not strictly en-
forced, and only 50% of individuals
with A1C data had true FPG measure-
ments based on case report forms. We
have not attempted to divide the treat-
ment populations by sex, ethnicity, indi-
vidual antidiabetic drug treatment,
cardiovascular drug treatment, or study
site, since the number of patients with
glycemic data would have been limiting.
In conclusion, ranolazine in addition
to its anti-anginal and anti-ischemic ac-
tion has clinically meaningful effects on
glucose and A1C in coronary artery dis-
ease patients receiving standard of care
diabetes treatment. The magnitude of the
effect on glycemic control is increased in
patients with elevated FPG or A1C. In pa-
tients with normal glucose, ranolazine
doesnotlowerFPGcomparedtoplacebo.
Although there are insufﬁcient data to
conclusively state that ranolazine does
not cause hypoglycemia, there is no evi-
dence that patients treated with ranola-
zine were more likely than those in the
placebo group to develop hypoglycemia.
The mechanism of action of ranolazine to
lower FPG and A1C is currently being in-
vestigated, however preliminary data
Figure 2—Effect of concurrent antidiabetes drug treatment on patients treated with ranolazine
reaching an A1C goal of 7%. Patients with a history of diabetes who were hyperglycemic at
randomization (A1C 7%) were grouped by drug treatment. These patients were reexamined at
4 months and categorized as responders if A1C was 7%. OR for hyperglycemic patients in each
grouptoreachanA1C7%wascalculatedusingalogisticsanalysismodel(SASsoftware,Cary,
NC). Data are plotted as OR (95% CI). Ins, insulin.
Chisholm and Associates
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atic islets suggests that ranolazine may
promote glucose-stimulated insulin se-
cretion (18).
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